Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
Recruiting
Phase 4
Interventional Study
Atrial Fibrillation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 100
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 162 (estimated)
- Sponsor
- University of Illinois at Chicago · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common AF genetic risk allele modul…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* ≥ 18 years of age
* History of typical or early-onset symptomatic (≥2 episodes/month) paroxysmal/persistent AF
* ECG that was recorded within 1 month of randomization showing AF
* Eligible for both Flecainide(Class I) and Sotalol (Class III) AAD
* Able to give informed consent…
Contacts